For instance, combining JAK2 inhibitors with HDAC inhibitors like vorinostat or panobinostat may lead to re-expression of tumor suppressor genes and enhance leukemia cell differentiation, thus complementing the effects of JAK2 inhibition. Here, HDAC9 is linked to leukemia.